At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 103 enrolled
Drug / intervention
Truvada +1 moredrug
Likely dose
Truvada 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV)
The University of Texas Health Science Center, Houston·interventional·Posted Oct 5, 2010·Updated Feb 8, 2016
In Brief
A Phase 4 clinical trial evaluating Truvada and Raltegravir for HIV. Completed, enrolled 103 participants across 1 site.
Detailed Summary
This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Gilead Sciences
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartMay 2011
Primary CompletionDec 2013
Study CompletionAug 2015
TodayJul 2026
First PostedOct 5, 2010
Enrollment StartMay 1, 2011
Primary CompletionDec 1, 2013
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.7 years ago
Interventions
Truvadadrug
Tenofovir 200mg/emtricitabine 300mg once a day
Raltegravirdrug
Raltegravir 400mg twice a day